Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells

Towards an NK-like Phenotype that Compromises Function and Persistence

Francesco Mazziotta1,2,3, Lauren E. Martin1 , Daniel N. Eagan2,4, Merav Bar2,4,5, Sinéad Kinsella1 , Kelly G. Paulson2,4 , Valentin

- 4 Voillet^{6,7}, Miranda C. Lahman¹, Daniel Hunter¹, Thomas M. Schmitt^{1,2}, Natalie Duerkopp^{1,2}, Cecilia Yeung², Tzu-Hao Tang¹,
- 5 Raphael Gottardo^{8,9,10,11}, Yuta Asano¹, Elise C. Wilcox¹, Bo Lee¹, Tianzi Zhang¹, Paolo Lopedote¹², Livius Penter^{13,14,15}, Catherine
- *J Wu13 , Filippo Milano2,3, Philip D. Greenberg1,2,16* , Aude G. Chapuis1,2,3,4 **
- *Contributed equally
	- 1 Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
	- 2 Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
	- ³ Immunotherapy Integrated Research Center, Fred Hutch Cancer Center, Seattle, WA, USA.
	- 4 Division of Medical Oncology, University of Washington, Seattle, WA, USA.
	- 5 Bristol Myers Squibb.
	- ⁶ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
	- 7 Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
	- ⁸ Biomedical Data Science Center, Lausanne University Hospital.
	- ⁹ University of Lausanne, Lausanne, Switzerland.
	- ¹⁰ Agora Translational Research Center, Lausanne, Switzerland
	- 11 Swiss Institute of Bioinformatics, Lausanne, Switzerland
	- 12 Department of Medicine, St. Elizabeth's Medical Center, Boston University, Boston, MA, USA.
	- ¹³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
	- ¹⁴ Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
	- ¹⁵ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Berlin, Germany
		- ¹⁶ Departments of Immunology and Medicine, University of Washington, Seattle, WA, USA.

 Corresponding Author: Aude G. Chapuis, MD Division of Hematology and Oncology, University of Washington Fred Hutchinson Cancer Center Phone: 206-667-4369; E-mail[: achapuis@fredhutch.org](mailto:achapuis@fredhutch.org)

Funding:

 We received funding from grant no. P01CA18029-41 (P.D.G.), grant no. NIH-5K08CA169485 (A.G.C.), the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Research Center (A.G.C.), Damon Runyon (A.G.C.), the Guillot Family ZachAttacksLeukemia Foundation, Parker Institute for Cancer Immunotherapy (P.D.G.), Gabrielle's Angel Foundation, the V Foundation, and Juno Therapeutics.

Conflicts of interest:

 A.G.C. has received support from Juno Therapeutics, Lonza, and Affini-T. P.D.G. is a consultant, has received support from and had ownership interest in Juno Therapeutics and Affini-T Therapeutics. He has also received support from Lonza, and consults and has ownership interest in Rapt Therapeutics, Elpisciences, Immunoscape, Earli, Metagenomi. Catalia, and Nextech. P.D.G., T.M.S., H.N.N. and the Fred Hutchinson Cancer Research Center have intellectual property related to TCR-C4. A.G.C. and K.G.P. have received reagents from 10X Genomics. R.G. has received consulting income from Takeda, Arcellx and Sanofi, and declares ownership in Ozette Technologies.. The authors declare no other competing interests.

Data sharing

For original data, please contac[t fmazziot@fredhutch.org](mailto:fmazziot@fredhutch.org) an[d achapuis@fredhutch.org.](mailto:achapuis@fredhutch.org) Raw data will be deposited and made publicly available as per journal requirements.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

60 **Abstract**

 Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk 63 patients was prevented by post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8⁺ 64 T cells engineered to express a high-affinity Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (T_{TCR} - $_{\text{C4}}$). However, in the present study, infusion of EBV- or Cytomegalovirus (CMV)-specific T_{TCR-C4} did not 66 clearly improve outcomes in fifteen patients with active disease post-HCT. TCR_{C4}-transduced EBV-specific 67 T cells persisted longer post-transfer than CMV-specific T cells. Persisting $T_{TCR\text{-}C4}$ skewed towards dysfunctional natural killer-like terminal differentiation, distinct from the dominant exhaustion programs reported for T-cell therapies targeting solid tumors*.* In one patient with active AML post-HCT, a sustained T_{TCR-C4} effector-memory profile correlated with long-term T_{TCR-C4} persistence and disease control. These findings reveal complex mechanisms underlying AML-induced T-cell dysfunction, informing future therapeutic strategies for addressing post-HCT relapse.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

73 **Introduction**

 Relapsed/refractory acute myeloid leukemia (AML) after allogeneic hematopoietic cell 75 transplantation (HCT) poses a major therapeutic challenge, $1,2$ with 2-year overall survival (OS) rate below 20% and only 4% if relapse occurs within six months post-HCT.¹⁻³ Salvage therapies, including intensive chemotherapy, donor lymphocyte infusions (DLI), and second HCTs have shown limited efficacy, underscoring the urgent need for novel therapies.

79 The Wilms' Tumor 1 (WT1) protein is an attractive AML immunotherapy target,⁴ as WT1 80 overexpression promotes proliferation and oncogenicity.⁵⁻⁷ In a phase I/II trial, targeting WT1 in the post-81 HCT setting, we genetically modified matched donor CD8⁺ T cells to express a high-affinity WT1-specific 82 T cell receptor (TCR_{C4}) specific for the HLA-A*0201-restricted WT1₁₂₆₋₁₃₄ epitope. To minimize the 83 potential for graft-versus-host disease (GVHD) mediated by infused donor cells,⁸ Epstein-Barr virus 84 (EBV)-specific or cytomegalovirus (CMV)-specific (in EBV-negative donors) $CD8⁺$ T cells were 85 transduced (T_{TCR-C4}). Prophylactic infusion of EBV-specific T_{TCR-C4} in patients without detectable disease, 86 but at high relapse risk post-transplant (Arm 1), yielded 100% relapse-free survival in 12 patients at a 87 median follow-up of 44 months, and 54% in concurrent controls.⁹ However, in 15 patients with prior 88 evidence of disease post-HCT discussed here, infused EBV-specific or CMV-specific T_{TCR-C4} did not yield 89 a superior overall survival compared to historical controls.^{1,2,10,11}

90 The persistence of functional antigen-specific T cells is required for sustained immunotherapy 91 efficacy.¹²⁻¹⁴ In solid tumors and lymphomas, reduced persistence generally correlates with T-cell 92 exhaustion,^{12,15,16} characterized by markers like PD-1, CTLA-4, Tim3, LAG-3, BTLA and/or TIGIT.¹⁷ 93 Targeting these immune-inhibitory receptors with checkpoint-blocking antibodies mitigates exhaustion.^{18,19} 94 In AML, recent studies have questioned the presence of T-cell exhaustion,²⁰ proposing alternative 95 mechanisms of immune dysfunction.^{21,22} Natural killer-like (NKL) markers expressed on CD8⁺ T cells have 96 correlated with adverse outcomes, suggesting that NKL skewing may contribute to T-cell dysfunction.²²⁻²⁴ 97 However, whether AML directly induces terminally differentiated, dysfunctional antigen-specific T cells 98 remains unclear.²⁵

 Understanding the mechanisms of dysfunction that are operative in AML is critical for designing 100 strategies to overcome the current limitations observed in T-cell therapies. Adoptive transfer of T_{TCR-C4} in refractory or relapsed AML patients has provided a unique opportunity to track AML-specific T cells, elucidate AML-induced T cell states, identify the mechanisms responsible for T-cell dysfunction, and inform the design of effective anti-AML therapies.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

104 **Results**

105 **TTCR-C4 is safe, well tolerated, and produces comparable outcomes to conventional treatments for**

106 **high-risk relapsed/refractory AML patients post-HCT.**

 From December 2012 through March 2020, 15 HLA-A2-expressing patients with relapsed and/or refractory AML post-HCT were enrolled on trial NCT01640301 **(Table 1, Extended data Fig. 1)**. The median age at diagnosis was 40. Pre-HCT, 27% of patients had secondary or treatment-related AML, at diagnosis 47% were adverse risk, and 53% favorable/intermediate risk per European LeukemiaNet (ELN) 111 stratification (Supplementary Table 1).²⁶ Post-HCT, four patients had measurable residual disease (MRD) by ~28 days (refractory), two relapsed by 3 months, and nine relapsed after day 100. The median time to 113 relapse was 496 days post-HCT. Thirteen patients received salvage therapy before T_{TCR-C4} , including six who underwent a second HCT. Within a median of two weeks before infusion, two patients had overt disease, five were MRD-positive and the rest had no evaluable disease (NED) **(Extended data Fig. 2)**. Ten 116 patients received EBV-specific T_{TCR-C4} and five received CMV-specific T cells **(Table 1)**. Patients received 117 one to four infusions depending on their place in the T_{TCR-C4} dose escalation **(Extended data Fig. 3)**.

118 As in Arm 1 , T_{TCR-C4} infusions were safe and well tolerated **(Supplementary Table 2)**. The 119 incidence of acute and chronic GVHD (aGVHD, cGVHD) was lower compared to DLIs or second HCTs 120 as salvage strategies, ^{11,27} with only one patient (7%) developing grade 3 aGVHD and three (20%) 121 developing cGVHD post- T_{TCR-C4} infusion. Post-infusion cGVHD included one grade 3, one grade 2 and 122 one grade 1 cGVHD. However, the onset of cGVHD occurred when T_{TCR-C4} constituted <1% of the 123 peripheral blood (PB) $CD8^+$ T cells, making the infusion of T_{TCR-C4} with an endogenous virus-specific TCR 124 the unlikely cause of cGVHD.

125 Among the patients enrolled **(Table 1)**, four showed no overt relapse and/or MRD following T_{TC} -126 $_{\text{C4}}$ infusion(s) **(Extended data Fig. 4)** supporting $T_{\text{TCR-C4}}$'s potential biologic activity. However, when all 127 15 patients were analyzed together, the median OS was 242 days, the 2-year OS was 33%, and the 3-year 128 OS was 20% **(Extended data Fig. 5)**, indicating that these individual outcomes did not translate into a 129 significant survival advantage over historical salvage treatments.^{1,2,10,11} For example, DLI post-HCT relapse 130 showed a 2-year OS of 21% $(\pm 3\%)$ from relapse and 56% $(\pm 10\%)$ from DLI in cases of remission or with 131 a favorable karyotype, dropping to 15% (\pm 3%) in aplasia or active disease.²⁷

132

133 **Virus-specific substrate T cells and AML presence at the time of infusion are major determinants of** 134 **T**_{TCR-C4} **persistence**

135 In our cohort, baseline PB WT1-specific tetramer⁺ T cells were low (**Fig. 1A** – red arrows, day 0) 136 indicating limited endogenous WT1-specific T cells. By day 28 post-infusion, four patients showed T_{TCR} 137 $_{\text{c4}}$ levels exceeding 3% (persistence threshold) of the CD8⁺ T cells, with three maintaining these levels

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

138 beyond day 100. Higher frequencies correlated with increased absolute T_{TCR-C4} counts **(Extended data Fig.**)

139 **6A)**. Patients with T_{TCR-C4} frequencies below 3% were eligible for additional infusions (two infusions in

140 6/15 patients, >2 infusions in 4/15 patients) **(Table 1)**. However, more than two infusions did not

141 significantly increase persistence (**Fig. 1B**).

142 We next explored the contribution of substrate cell virus-specificity to post-infusion persistence. 143 Within 28 days, EBV-specific T_{TCR-C4} were more abundant than CMV-specific T_{TCR-C4} , which remained 144 below the persistence threshold **(Fig. 1C)**. These differences endured when EBV-specific T_{TCR-C4} recipients 145 from Arm 1 were included (Extended data Fig. 6B).⁹ As central-memory CD8⁺ T cells (Tcm) have shown 146 improved persistence compared to more differentiated phenotypes post-transfer,²⁸ we sought to explore 147 whether differences in endogenous virus-specific cells could recapitulate these findings. We analyzed the 148 phenotypes of EBV- and CMV-specific T cells using mass cytometry data²⁹ from 143 healthy individuals 149 and cancer patients. Multidimensional scaling (MDS) showed segregation of CMV- and EBV-specific 150 CD8⁺ T cells along the first dimension (MDS dim.1) suggesting distinct T-cell differentiation states 151 between these groups (Extended data Fig. 7A). Next, Flow Self-Organizing Maps (FlowSOM)³⁰ 152 metaclustering identified four CD8⁺ T-cell subsets: naïve (CD95⁻,CD45RA⁺, CCR7⁺, CD27⁺, CD28⁺), 153 effector memory (Tem) (CD95⁺, CD45RA⁻, CD45RO⁺, CD27⁺, CD28⁺, CD127⁺), Tcm (CD95⁺, CD45RA⁻ 154 , CD45RO⁺, CCR7⁺, CD27⁺, CD28⁺, CD127⁺), CD45RA⁺ effector memory (Temra) (CD95⁺, CD45RA⁺, 155 CD45RO, CD57⁺, KLRG1⁺) (Extended data Fig. 7B).^{31,32} Differential abundance analysis revealed a 156 significant (false discovery rate/FDR < 0.05) increase of Temra cells in CMV-specific T cells and of naïve, 157 Tcm and Tem in EBV-specific T cells**(Fig. 1D)**. These results suggest that the Temra state of CMV-specific 158 substrate cells compromises post-infusion persistence, whereas EBV-specific cells, derived from less 159 differentiated precursors, facilitate persistence.

160 Persistence varied among EBV-specific $T_{TCR\text{-}c4}$ recipients, **(Fig. 1C, Extended data Fig. 6A)**, with 161 only three of ten (4, 8 and 27) exhibiting long-term persistence (>100 days post-infusion) **(Fig. 1A,** 162 **Extended data Fig. 8A**). We reasoned that persistence was influenced by AML high-risk factors, including 163 post-transplant remission duration and disease burden at the time of T_{TCR-C4} infusion.³ Patient 1 was 164 excluded from this analysis due to unavailable WT1-expression data. Six of the remaining patients did not 165 show long-term persistence: four (5,7,14, and 19) had detectable disease (MRD or overt) within two weeks 166 of $T_{TCR\text{-}C4}$ infusion, and two (23, 26) who were disease-free at infusion, had relapsed within 3 months post-167 HCT, suggesting difficult-to-control disease. Statistical testing revealed a trend (Fisher's exact test, $p =$ 168 0.08) linking reduced persistence with "aggressive" disease (defined as having detectable disease pre-169 infusion or early relapse post-HCT). Patient 8, initially categorized as "aggressive" because MRD-positive 170 before the first infusion, became MRD-negative through salvage therapy before the second infusion, 171 achieving the longest observed T_{TCR-C4} persistence. Reclassifying this patient as "non-aggressive", renders

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

172 the association between disease aggressiveness and persistence statistically significant ($p < 0.05$). These

173 findings suggest that aggressive disease post-HCT, independently of virus-specificity, was associated with

- 174 reduced T_{TCR-C4} persistence *in vivo*.
- 175

176 **Long-term persistent TTCR-C4 acquire NKL/terminal differentiation markers associated with** 177 **progressive loss of function** *in vivo*

178 To investigate the fate of T_{TCR-C4} post-transfer in patients with persistent T_{TCR-C4} , and compare these 179 with endogenous (TCR_{C4}) T cells, we designed a 24-color spectral flow-cytometry panel **(Supplementary** 180 **Table 3**). PB was analyzed at \sim 1 (T1), \sim 7 (T2), 28 (T3) days, and \sim 4 months (T4) post-transfer **(Supplementary Table 4)**. FlowSOM clustering revealed five CD8⁺ T-cell states categorized into three higher-level clusters **(Fig. 2A, top dendrogram)**: naïve-/cm-like cells **(Fig. 2A, dark green)** (CD45RA⁺, 183 CCR7⁺, CD27⁺, CD28⁺); Tem subgroup, including endogenous CD8⁺ Tem (CD28⁺, CD27⁺, Ki67⁺, CD38⁺, 184 TIGIT⁺, PD1⁺, Tbet⁺) (Fig. 2A, violet), and phenotypically similar T_{TCR-C4} Tem (tetramer⁺) (Fig. 2A, blue); 185 Temra subgroup of endogenous CD8⁺ T cells (CD45RA⁺, CD57⁺, KLRG1⁺, GZMB⁺) (Fig. 2A, light green) 186 and closely clustered T_{TCR-C4} Temra **(Fig. 2A, red)**. Two-dimensional Uniform Manifold Approximation 187 and Projection (UMAP) revealed a progressive increase in T_{TCR-C4} Temra and decline in T_{TCR-C4} Tem from 188 T1 to T4 **(Fig. 2B)**. T_{TCR-CA} Temra expressed minimal Ki67 compared to T_{TCR-CA} Tem (**Fig. 2A**), enabling 189 manual gating of these two subsets (Fig. 2C). Over time, T_{TCR-C4} Temra significantly increased, while T_{TCR} -190 $_{\text{C4}}$ Tem decreased (p <0.05) **(Fig. 2D)**, suggesting differentiation from proliferative T_{TCR-C4} Tem to non-191 proliferative T_{TCR-C4} Temra. T_{TCR-C4} Temra predominantly expressed cytotoxic/KLR markers (KLRG1, 192 $CD57$, GNLY), previously linked to T-cell dysfunction in AML , $21-23$ rather than classical T-cell exhaustion 193 markers (Tim3, PD1, and TIGIT) (Fig. 2E).^{17,33} Stratification by timepoint revealed progressive increase 194 of the cytotoxic subset versus the exhausted subset **(Fig. 2F)**. This phenotypic shift concided with a detectable but slow decline in T_{TCR-C4} CD8⁺ T cells producing IFN γ and TNF α (Fig. 2G, Extended data 196 **Fig. 8B).** Thus, long-term persisting EBV-specific T_{TCR-C4} skew towards a distinct NKL phenotype linked 197 to functional decline.

198

199 **TTCR-C4 largely represent an intermediate state between effector memory and NK-like/terminally** 200 **differentiated cells.**

201 To explore the relationship between CDS^+ endogenous T-cell and T_{TCR-CA} states, we performed 202 single-cell RNA sequencing (scRNAseq) on available PB and bone marrow (BM) samples from patients 203 with T_{TCR-C4} exceeding 3% of CD8⁺ T cells at least until day 28 post-infusion. This analysis included two prophylactic9 204 and five treatment-arm patients **(Supplementary Table 5)**.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

205 Unsupervised clustering of PB CD8⁺ T cells (n = 24,472) identified 13 clusters, with the TCR_{C4} transgene expressed across several clusters, but primarily in cluster 2 **(Fig. 3A)**. Using the marker-based 207 purification algorithm scGate,³⁴ we identified TCR_{C4}^+ cells **(Fig. 3B)** labeled as T_{TCR-C4} , while endogenous (TCRC4– 208) T cells included clusters 5 and 6,labeled as naïve-/cm-like, expressing *CCR7*, *SELL*, *TCF7*, *LEF1*, *IL7R*; clusters 2, 4 and 11, labeled as Tem, expressing genes associated with activation (*CD69*, *TIGIT*, *GZMK*); cluster 12, labeled as interferon signaling genes (ISG), expressing *ISG15*, *ISG20*, *IRF7*, *IFI6*; clusters 9 and 10, labeled as T memory/proliferative (Tmem/prolif), expressing proliferation (*MKI67*, *MCM5*, *MCM7*) and memory (*CD27*) genes; clusters 0,1,3,7, and 8, labeled as NKL/Temra, expressing genes associated with cytotoxicity/NKL (*KLRF1*, *KIR3DL1*, *NKG7*, *FCGR3A*, *GZMB*, *KLRD1*, *PRF1*)

214 **(Fig. 3A-C, Extended data Fig. 9A-C, Supplementary Table 6)**.

215 To assess transcriptional similarities among cell states, we performed principal component 216 analysis, positioning naïve-/cm-like and NKL/Temra as differentiation spectrum extremes, with T_{TCR-C4} as 217 the intermediate state between these two extremes **(Fig. 3C)**.

218 To ensure unbiased labeling of CD8⁺ T cells, we constructed a scRNAseq reference atlas 219 comprising 109,051 CD8⁺ T cells, using a published scRNAseq dataset of tumor-infiltrating lymphocytes.³⁵ 220 We aligned and projected our scRNAseq dataset onto the reference atlas **(Extended data Fig. 9B)**, 221 confirming the correspondence between the transcriptional states in our dataset and the reference. 222 Differential gene expression (DGE) analysis using manually curated markers further supported this 223 annotation (Supplementary Table 7, Extended data Fig. 9C).^{31,32,36,37}

224 Consistent with previous work,³² we observed a progressive reduction of stem-like markers (*IL7R*, 225 *TCF7*) from naïve/cm-like cells through Tem and NKL/Temra cells, while activation markers (*CD69*, 226 *GZMK*) peaked in Tem. NKL markers, including KLR-exhaustion markers (*S1PR5*, *ZEB2*),^{38,39} were 227 highest in NKL/Temra. T_{TCR-CA} expressed activation and NKL markers, reflecting an intermediate state 228 between Tem and NKL/Temra (**Extended data Fig. 9D**).

229 Monocle⁴⁰ trajectory inference confirmed T_{TCR-C4} as an intermediate state between Tem and the 230 terminal NKL/Temra state **(Fig. 3E-F)**, and removing the TCR_{C4} transgene did not alter this differentiation 231 trajectory **(Extended data Fig. 10A-B).** Single-gene expression over pseudotime revealed early peaks of 232 naïve/stem-like markers (*CCR7*, *IL7R*, *TCF7*, *SELL*, *LEF1*) (**Fig. 3G, first row**), naïve/memory (*CD27*, 233 *CD28*) and activation markers (*GZMK*, *CD69*), with the latter remaining high throughout mid-pseudotime 234 before declining. **(Fig. 3G, second row)**. TCR_{C4} expression peaked at mid-pseudotime, but remained 235 expressed until the end of pseudotime. NKL/Temra-associated genes (*PRF1*, *KLRG1*, *NKG7*, *ZEB2*, **236** *S1PR5*) peaked at the end of pseudotime **(Fig. 3G, third row)**. RNA velocity inference⁴¹ supported the 237 spectrum of differentiation from naïve-like to Tem and T_{TCR-C4} , culminating in NKL/Temra cells (**Fig. 3H**).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

238 Overall, our findings suggest that T_{TCR-C4} largely existed in an intermediate state between the Tem 239 phenotype and the NKL/Temra stage.

240

241 AML drives T_{TCR-C4} towards NKL/terminal differentiation instead of the dominant exhaustion 242 **pattern associated with T cells in solid tumors.**

243 To investigate AML's impact on the differentiation of endogenous $CD8⁺$ T cells and T_{TCR-CA} , 244 patients samples were grouped as AML- (no AML detected, including two prophylactic arm cases), 9 or 245 AML+ (blasts evident in BM and/or PB) **(Supplementary Table 8)**. The increase of ISG and NKL/Temra 246 in AML+ and T_{TCR-C4} in AML- (Fig. 4A) was significant (Fig. 4B), with a wide confidence interval for ISG, 247 making the magnitude of this difference unclear. T_{TCR-C4} overexpressed NKL/Temra genes in AML+ 248 compared to AML- **(Fig. 4C)**, suggesting that AML blasts may induce a transcriptional shift towards 249 NKL/Temra in T_{TCR-C4} and endogenous T cells.

- 250 Following previously described methodology,⁴² we exposed *in vitro* CD8⁺ transgenic WT1-specific 251 T cells targeting the HLA A*0201-restricted WT1 $_{37-45}$ epitope⁴³ (T_{TCR37-45}) to high-WT1-expressing HLA-252 A*0201-transduced K562 acutely transformed chronic myelogenous leukemia **(Extended data Fig. 11A)**. 253 As K562 primarily express standard proteasomes and are not readily lysed by T_{TCR-C4} targeting the 254 immunoproteasome-specific WT1_{126–134} peptide, we used $T_{TCR37-45}$ due to its proteasome-agnostic WT1-255 derived peptide recognition.⁴³ Exposing T_{TCR37-45} to fresh K562 every 3-4 days at stable effector-to-target 256 (E:T) ratios (1:1, 1:4) caused initial tumor lysis **(Extended data Fig. 11B)**, but control was lost by day 13, 257 marked by a declining $T_{TCR37-45}$ -to-tumor ratio **(Extended data Fig. 11C)**. Irrelevant TCR-expressing T 258 cells exerted no control **(Extended data Fig. 11D)**. Bulk-RNA sequencing on sorted T cells found increased 259 (FDR <0.05) naïve/stem-like genes (*IL7R, TCF7, LTB*, *LEF1*, *SELL*) at day 0, followed at day 13 by 260 increased effector (*CCL5, GZMK*), activation/exhaustion (*CD69*, *LAG3*, *CTLA4*, *PDCD1*), and 261 NKL/Temra markers (*KLRB1*, *ENTPD1*, *KLRC1*, *KLRC2, NCAM1*) **(Fig. 4D-E)**. By day 23, the 262 activation/exhaustion markers decreased, while NKL/Temra persisted or increased **(Fig. 4D-E)**. To 263 integrate these findings with the scRNAseq dataset, we performed a gene-set enrichment analysis with the 264 top 50 differentially expressed genes from each $CD8^+$ subset identified in scRNAseq, including naïve-/cm-265 like, Tem, NKL/Temra, $T_{TCR\text{-}C4}$, Tmem/prolif and ISG from the scRNAseq dataset. We also included a 266 manually curated exhaustion signature **(Supplementary Table 9)**. Exhaustion and Tem signatures 267 exhibited enrichment in later timepoints, yet there was no further increase at day 23 versus day 13 **(Fig. 268 4F)**. In contrast, the NKL/Temra increased between days 13 and 23 corresponding to $T_{TCR37-45}$ loss of tumor 269 control **(Extended data Fig. 11C)**.
- 270 We next projected scores from published NKL dysfunction signatures^{22,38,39} onto our UMAP, 271 revealing overlaps that link the NKL/Temra $CD8⁺$ T cells we identified with an end-term dysfunctional

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 differentiation subset **(Extended data Fig. 12)**. To confirm that AML-exposed T cells skewed towards a NKL/Temra rather than exhausted (Tex) phenotype, we projected onto a scRNAseq reference atlas a BM 274 AML CDS^+ T-cell dataset, compiled from published sources, $20,22,23,44,45$ alongside datasets representing 275 pancreatic,⁴⁶ melanoma,⁴⁷ and lung⁴⁸ solid tumors (Fig. 4G-H).³⁵ Unlike solid tumors, which included a Tex cluster, AML datasets aligned with our spectral flow-cytometry and scRNAseq findings confirming the absence of Tex and the presence of NKL/Temra cells (**Fig. 4G**, **Extended data Fig. 13**). Although these studies did not specifically analyze tumor-antigen reactive T cells, the findings collectively suggest that the NKL (versus exhaustion) signature is intricately associated with AML-induced T-cell dysfunction.

280

281 Prolonged azacitidine exposure enhances self-renewal and Tcm features of T_{TCR-G4} , supporting T_{TCR} 282 **C4-mediated AML control**

283 Given the link between NKL differentiation and AML-induced T-cell dysfunction, we explored the 284 state of T_{TCR-C4} in patient 8, the only patient of 4 **(Extended data Fig. 4)** who exhibited prolonged T_{TCR-C4} 285 and MRD persistence indicative of disease control despite incomplete leukemia clearance, enabling T_{TCR} -286 C_4 /AML interplay analysis. This female patient underwent a non-myelo-ablative (Flu/3Gy-TBI) HCT from 287 a male donor, with MRD (0.26% blasts by flow cytometry) detected 28 days post-HCT **(Fig. 5A)** and 288 received a T_{TCR-C4} (10¹⁰ cells/m²) 77 days post-HCT. AML blasts expressed detectable but limited WT1 289 protein pre-HCT **(Extended data Fig. 14).** scRNAseq at day 49 post-infusion revealed circulating CD34⁺ 290 female-origin blasts (XIST⁺) expressing WT1 **(Fig. 5E-F)**. Persistent MRD and limited T-cell persistence 291 at day 63 post-infusion (T cells declined to only 0.1 multimer⁺ CD8⁺ T cells/ μ l on day 60), **(Fig. 5B, 5C**-292 **red arrow, 5D)** prompted azacitidine treatment (five days every 28 days). Post-azacitidine, T_{TCR-C4} counts 293 increased (~50 multimer⁺ CD8⁺ T cells/ul; >3% CD8 multimer⁺ T cells) without additional T_{TCR-CA} **(Fig.**) 294 **5D)**, leading to azacitidine discontinuation after seven cycles when no AML was detected. However, AML 295 recurrence at day 414 post-infusion triggered chemotherapy (mitoxantrone, etoposide and cytarabine), 296 additional azacitidine cycles followed by a second T_{TCR-C4} (10^{10} cells/m²) infusion **(Fig. 5A)**. Azacitidine 297 was held post-infusion but restarted upon MRD detection 162 days post-second T_{TCR-C4} infusion, continuing 298 for over 20 monthly cycles, maintaining marrow MRD below 1% for 21 months (641 days, from day 868 299 to day 1509) before progression was detected on day 1546 **(Fig. 5A-B)**. During this 21-month period, blasts 300 were detectable via scRNAseq in BM but not in PB **(Fig. 5F, Extended data Fig. 15A-B)**. Throughout the 301 azacitidine cycles, platelet counts decreased $(\sim 100 \times 10^3 \text{ platelets/}\mu\text{I})$ mid-cycle before rising $(\sim 300 \times 10^3 \text{ Hz})$ 302 platelets/µl) immediately before the next cycle, consistent with transient azacitidine-mediated 303 myelosuppression. Neutrophil counts, however, paradoxically increased mid-cycle (-4.5×10^3) 304 neutrophils/ μ l) and decreased (~1.6 x 10³ neutrophils/ μ l) just before the next cycle, suggesting that 305 treatment-related AML contraction facilitated enhanced mid-cycle neutrophil production despite

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

306 azacitidine's myelosuppressive effect **(Extended data Fig. 15C)**. This 21-month response exceeds the 307 typical 4-month median for post-HCT azacitidine treatment,⁴⁹ suggesting that persisting T_{TCR-C4} plus 308 azacitidine contributed to long-term disease control.

 309 T_{TCR-C4} transcriptomics were analyzed to identify associations with disease control. We scored 310 genes associated with self-renewal and NK-like profiles and found that at earlier timepoints (d49, d256, 311 and d405 post-first infusion), T_{TCR-C4} were predominantly skewed towards an NKL/Temra transcriptional 312 state. However, at later timepoints (d1322, d1343) although T_{TCR-C4} remained along the same differentiation 313 trajectory (from less differentiated states to NKL/Temra T_{TCR-C4}), they exhibited fewer NKL features, and 314 showed an enrichment of self-renewal markers **(Fig. 5G-I)**. scTCRseq analysis of PB at days 265, 405, 315 1322, 1343 post-first T_{TCR-C4} infusion revealed progressive clonal expansion of T_{TCR-C4} (Fig. 5K). T_{TCR-C4} 316 clonal expansion peaked during the 21 months of continued azacitidine treatment, suggesting that during 317 this phase, T_{TCR-C4} were capable of both self-renewal, which in turn facilitated their long-term persistence, 318 and antigen recognition, which triggered further expansion and disease control. Similarly, BM scRNAseq 319 revealed clonal expansion of T_{TCR-C4} between d1322 and d1344 post-first infusion (**Fig. 5L**) despite no 320 additional $T_{TCR\text{-}c4}$. These findings indicate that azacitidine-exposed $T_{TCR\text{-}c4}$, retained a self-renewing (versus 321 NKL) features, which enabled their long-term persistence and enhanced AML-targeting efficacy that may 322 have contributed to long-term disease control **(Fig. 5M)**.

323

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

324 **Discussion**

325 We previously demonstrated that EBV-specific $T_{TCR\text{-}C4}$ infusion prevented AML recurrence in 326 patients at high risk of post-HCT relapse.⁹ In 15 AML patients who received T_{TCR-C4} post-HCT relapse, we 327 observed indirect anti-leukemic activity, but no survival advantage in those receiving EBV- or CMV-328 specific $T_{TCR\text{-}c4}$. We analyzed the AML/ $T_{TCR\text{-}c4}$ interplay to investigate how AML affects antigen-specific T 329 cells, and identified T-cell characteristics associated with AML control in one case.

330 The characteristics of substrate cells from which T-cell products are derived can impact post-331 transfer persistence. In murine and macaque models, antigen-specific Tcm-like CDS^+ T cells persist long-332 term post-adoptive transfer, unlike Temra-like cells.^{9,28} In our study, T_{TCR-C4} from EBV-specific persisted 333 longer compared to CMV-specific substrate cells which may reflect the distinct biology of EBV and 334 CMV.^{50,51} CMV reactivates periodically, requiring rapidly activated responses that promote Temra 335 differentiation,^{52,53} while EBV tends to remain quiescent, preserving Tcm phenotypes.⁵⁴⁻⁵⁶ While 336 reactivation frequency plays a role, the reactivation microenvironment is also critical. CMV reactivates in 337 non-professional antigen-presenting cells, including fibroblasts, which lack co-stimulatory signals and 338 favor Temra differentiation; EBV reactivates in lymphoid tissues B cells, providing co-stimulation that may 339 preserve the Tcm phenotype.^{57,58} Our analysis of an independent mass-cytometry dataset²⁹ confirmed that 340 EBV-specific cells better maintain self-renewing features than CMV-specific cells. Taken together these 341 findings establish that self-renewal may predict prolonged T-cell persistence.^{9,28} However, EBV-specific 342 T_{TCR-C4} were unable to sustain long-term responses in all patients, suggesting influence by non-intrinsic 343 AML-related factors.

344 Despite efforts to investigate T cell dysfunction in $\text{AML}^{20,21,23}$ several critical questions have 345 remained unanswered,²⁵ mainly due to the challenge of identifing AML-specific T cells. In this study, 346 infused T_{TCR-C4} offered the possibility of examining AML-specific T cell and AML biology. We found that 347 T-cell exhaustion is not the primary cause of AML-specific T-cell dysfunction.^{20,21,23} Instead, T_{TCR-C4} with 348 exhaustion markers (PD1, TIGIT, Tim3) also expressed activation markers (CD38, CD69) and proliferation 349 (Ki67), indicating an effector-like T-cell state. Overall, this suggests that AML-exposed T cells follow a 350 differentiation trajectory from effector-memory to NKL cells, compromising T_{TCR-C4} cell persistence and 351 function.

352 AML's distinct properties, including myeloid cells immunosuppressive effects⁵⁹ via production of 353 reactive oxygen species and other soluble factors, may distinctly redirect T cells toward functional 354 impairment that may preclude transitioning to a classical exhausted phenotype and explain the observed 355 NKL skewing in T_{TCR-C4} and endogenous CD8⁺ T cells. The absence of classical exhausted cells in AML 356 has several implications. In solid tumors, chronic antigen stimulation induces a multi-step epigenetic shift 357 of CD8⁺ T cells into exhaustion,⁶⁰ starting from PD1⁺TCF1⁺ precursor/progenitor exhausted cells,^{23,24}

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

358 whose frequency correlates with response to checkpoint inhibitors.^{9,28} In contrast, our AML findings suggest 359 that exhaustion markers reflect recent T cell activation rather than true exhaustion, which may also explain 360 the limited efficacy of checkpoint inhibitors in AML.^{20,23,24,61} The presence of a distinct dysfunctional 361 program supports new immunotherapy strategies to enhance the efficacy of anti-AML adoptive T-cell 362 therapy, preventing T-cell dysfunction. For example, knocking out ID3 and SOX4 transcription factors in 363 chimeric antigen receptor-engineered (CAR)-T cells *in vitro* reduces NKL skewing and enhances effector functions. 364 ⁴² Whether these strategies can improve cell therapy in AML *in vivo* remains to be determined.

365 Another strategy to reduce NKL skewing of T_{TCR-C4} , as suggested by the outcome in one of our 366 treated patients, could involve the hypomethylating agent azacitidine. While azacitidine has direct anti-367 leukemia effects, 62 the prolonged disease control observed in our patient was unusual prompting further 368 investigation into the mechanisms at play. Azacitidine administration correlated with clonal expansion and 369 persistence of central memory, as opposed to NKL differentiated T_{TCR-CA} , leading to a prolonged equilibrium 370 between anti-leukemic T_{TCR-C4} and AML MRD. Before the first T cell infusion in this patient, low AML 371 WT1 expression likely did not activate T_{TCR-C4} , causing their near disappearance. However, after azacitidine 372 introduction, T_{TCR-CA} frequencies increased, likely driven by azacitidine-induced WT1 expression.⁶³ 373 Intermittent T_{TCR-C4} activation by WT1 presentation on AML cells transiently induced by cycles of 374 azacitidine with subsequent temporary clearance of AML may have helped sustain T_{TCR-C4} persistence and 375 response to stimulation. Other studies have shown that azacitidine can have negative effect on T regulatory 376 cells⁶⁴ and boosts CAR T cell toxicity towards AML.⁶⁵ Further investigation is needed to determine if 377 azacitidine acts preferentially on leukemia cells by increasing WT1 expression thereby promoting antigen-378 recognition and/or T_{TCR-C4} effector functions. However, taken together, these findings support azacitidine as 379 a favorable adjunct to T cell immunotherapy.

380 Paradoxically, our ability to track dysfunction was limited to patients with persisting T_{TCR-CA} , where T cells were relatively more functional. We hypothesize that patients with more aggressive disease experience accelerated T-cell dysfunction and death rather than establishment of progenitor cells capable of self-renewal; however we were unable to formally test this in our study. Despite a limited sample size, our findings on the nature of T-cell dysfunction in AML were confirmed in larger cohorts of endogenous CD8⁺ T cells, though further validation in larger trials could provide more detail. Additionally, our 386 interpretation of the effect of azacitidine on T_{TCR-C4} is based on a single patient. To address this limitation, we are initiating a clinical trial of co-administration of azacitidine and TCR-T cells.

388 Our study illuminates some of the complex mechanisms underlying AML-induced T cell 389 dysfunction and strengthens support for a distinct pathway outside the traditional paradigm of T cell 390 exhaustion, emphasizing the need to addres this unique dysfunction in future immunotherapy strategies.

391

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Methods

Clinical protocol

 The trial was approved by the Fred Hutchinson Cancer Center (FHCC) Institutional Review Board, the US Food and Drug Administration and the National Institutes of Health Recombinant DNA Advisory Committee. It was registered at ClinicalTrials.org under the identifier NCT01640301. Eligible participants

- included 'high-risk' AML patients with relapsed or refractory disease (overt or MRD) post-HCT along with
- their fully HLA-matched (10 of 10) related or unrelated donors expressing HLA A*0201 (HLA-A2).

Patient selection

- HLA-A2 genotype was confirmed by high-resolution typing before enrollment. Exclusion criteria included:
- 402 refractory central nervous system disease, HIV seropositivity, grade \geq 3 GVHD and no available
- CMV/EBV-seropositive matched donor. The sample size for this study was not based on formal power
- calculations, but on feasibility, the potential to provide descriptive information, determine whether further
- study was warranted and evaluate toxicity.

Treatment plan

- 407 Isolation of TCR_{C4} , lentiviral vector construction, and T_{TCR-C4} generation were performed as previously
- 408 described.⁹ Patients were eligible to receive a first infusion of T_{TCR-C4} after demonstrating relapse (overt or
- MRD) at any time post allogeneic HCT. Patients 26,27,28 received lymphodepleting treatment before the
- 410 first T_{TCR-C4} infusion with cyclophosphamide (300 mg/m² IV) and fludarabine phosphate (30 mg/m² IV)
- 411 daily on days -4 to -2. A second T_{TCR-C4} infusion was administered only if the frequency of T_{TCR-C4} was <3%
- 412 of total peripheral CD8⁺ T cells. Patients 5,7,19,23,27 received 1 infusion, patients 4,8,15,26,28 received 2
- infusions, patient 1 received 1 infusion, the remainder received 4 infusions (**Table 1**). Patients were
- monitored for toxicities, based on Common Toxicity Criteria v.4.0.

Assessment of disease status

- Morphology, multiparameter flow cytometry, standard cytogenetics or genomic technologies were routinely
- performed on bone marrow aspirates and peripheral blood samples that were obtained from all patients.
- Any level of residual disease was considered to indicate positivity for MRD.

T cell tracking by WT1 peptide/HLA (pHLA) tetramers

- WT1 pHLA-specific tetramers (produced by the FHCC Immune Monitoring Core Facility) were used to
- 421 detect T_{TCR-C4} in PBMCs collected after infusions, with a staining sensitivity of 0.01% of total CD8⁺ T cells,
- 422 as previously described.⁹ T_{TCR-C4} percentages were calculated using FlowJo v.10 (Treestar).

Patient outcomes and survival analysis

- Kaplan-Meier OS curves were estimated using the *survminer* (v0.4.9) and *survival* (v3.3-1) packages in R.
- 425 OS was calculated from the date of first T_{TCR-C4} infusion to the date of death or censoring. Outcomes of
- responding patients were represented using a swimmerplot. Day 0 was defined as the post-HCT relapse

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

427 date or, for HCT-refractory patients, as day 28 post-HCT, at which timepoint persistent disease was

428 observed. R package *swimplot* (v1.2.0) was used for visualization.

429 Analysis of T_{TCR-C4} **persistence**

- 430 Persistence of TCR-T cells $(\%T_{TCR-C4})$ over time was visualized using *ggplot2* (v3.4.4) R package.
- 431 Wilcoxon rank-sum tests were used for pairwise comparisons between T_{TCR-C4} with different virus-
- 432 specificity (EBV vs. CMV) over time. Kruskal-Wallis tests were applied for multi-group comparisons**.**
- 433 Patients were categorized based on disease status prior to infusion: those with detectable MRD or overt
- 434 disease before T_{TCR-C4} infusion, or those who relapsed within 3 months post-HCT, were classified as having
- 435 "aggressive" disease. Patients without these risk factors were considered "non-aggressive." One patient was
- 436 excluded from the analysis due to the unavailability of WT1-expression data, which could confound
- 437 interpretation of the persistence results. Fisher's exact test was used to evaluate the association between
- 438 disease aggressiveness and T_{TCR-CA} persistence. The test was chosen due to the small sample size and binary
- 439 classification of persistence (long-term vs. short-term) and disease aggressiveness (aggressive vs. non-
- 440 aggressive). Statistical significance was assessed with a p-value threshold of 0.05.

441 **Flow-cytometry**

442 Cryopreserved PBMCs were thawed and allowed to rest overnight in RPMI medium supplemented with 443 10% fetal bovine serum (R10). The cells underwent stimulation with a cocktail containing the WT1₁₂₆₋₁₃₄ 444 peptide at a final concentration of 1 μ g/ml in R10 and intracellular cytokine staining using a 15-color 445 staining panel, as previously described.⁹ Flow cytometry was conducted on an LSRII instrument (Becton 446 Dickinson) with data acquisition using FACS-Diva software v.8.0.1. Flow cytometry data were 447 subsequently analyzed using FlowJo v.10 (Treestar). Finally, the percentage of Tetramer⁺cytokine⁺ cells 448 gated on the $CD8⁺$ T cell population was determined.

449 **Spectral flow cytometry**

- 450 Post-infusion PB samples were analyzed using a 5-laser Cytek Aurora. Antibodies used are listed in 451 **Supplementary Table 1**. TTCR-C4 were identified by binding to the APC dye-labeled HLA-A2:WT1126-
- 452 134 tetramer. Spectral flow-cytometry data were biexponentially transformed, compensated and
- 453 preprocessed (aggregates and dead cell removal) in FlowJo V10 (TreeStar). Pregated CD8⁺ T cells were
- 454 exported from FlowJo and loaded in R (v4.3.2). First we created a flowSet using *flowCore* (v2.12.2)⁶⁶ and
-
- subsequently analyzed the data using *CATALYST* (v1.24.0). ⁶⁷ 455
- 456 Ki67 was then used to manually gate subsets of interest using the FlowJo software. Statistical analysis
- 457 included Kruskal-Wallis to compare TTCR-C4_Temra and TTCR-C4_Tem percentages over time, and
- 458 Wilcoxon test for comparing $KLRG1^+CD57^+GNLY^+$ and $Tim3^+PD1^+TIGIT^+TTCR-C4_Temra.$
- 459 *In-silico* **mass cytometry validation**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

460 Mass cytometry files used to generate an atlas of virus-specific $CD8⁺$ T cells²⁹ were downloaded from

[https://zenodo.org/records/8330231.](https://zenodo.org/records/8330231) Data were analyzed using *flowCore* and *CATALYST* R packages as

specified above.

Single Cell RNA Sequencing

464 Patients with persisting PB T_{TCR-C4} (> 3% of the total CD8⁺ T cells) at least until day 28 after infusion were selected for scRNAseq analysis. Available PBMCs or BMMCs were thawed, washed and loaded on a 10x Chromium Controller based on the 3' Chromium or 5' Chromium Single Cell V(D)J Reagent Kit manual (10x Genomics). Library preparation was performed as per manufacturer's protocol with no modifications. Library quality was confirmed by TapeStation High Sensitivity (Agilent, evaluates library size), Qubit (Thermo Fisher, evaluates dsDNA quantity), and KAPA qPCR analysis (KAPA Biosystems, evaluates quantity of amplifiable transcript). Samples were mixed in equimolar fashion and sequenced on an Illumina HiSeq 2500 rapid run mode according to the standard 10X Genomics protocol. TCR target enrichment, 5' gene expression library, and TCR library were carried out to the 5' Chromium Single Cell V(D)J Reagent 473 Kit manual (10x Genomics). The 10X Genomics software Cell Ranger (v2.0.0) was used to process the raw 474 data FASTAQ files with default parameters. The EmptyDrops method⁶⁸ was used to identify cells with low RNA contents. The "count" function was used to perform alignment, filtering, barcode counting and UMI counting. Reads were aligned to the hg38 human reference genome (Ensembl) and the known transgene 477 codon-optimized sequence using Spliced Transcripts Alignment to a Reference (STAR).⁶⁹

 For V(D)J sequencing assembly and paired clonotype calling, we used CellRanger "vdj" function. This function leverages Chromium cellular barcodes and UMIs to assemble V(D)J transcripts for each cell. CellRanger V(D)J calling produces an output named "filtered_contig_annotations.csv" for each sample, which lists CDR3 amino acid and nucleotide sequences for single cells identified by their barcodes.

scRNAseq quality control and subsetting

 The filtered feature matrices generated by the CellRanger pipeline were used for downstream quality control (QC) and analyses. We used the function read10xCounts from the R package *DropletUtils* (version 485 1.14.2) to load the CellRanger output in R as a SingleCellExperiment⁷⁰ object. Doublet cells filtering was 486 performed on each sample using the *scds* package $(v1.10.0)$.⁷¹ QC and filtering were conducted using the $\,$ *scater* R package (v1.22.0)^{72.71} Genes not detected across all the cells were removed and cells were filtered based on feature counts, the percentage of mitochondrial and ribosomal genes, and the number of expressed features. Cells with values beyond a specific threshold, between 1 and 3.5 median absolute deviations (MAD) from the median, were excluded. These MAD thresholds were established according to the quality of each sample. Features with a count greater than 1 in at least 3 cells were retained for downstream analysis. We then split cells by sample in 15 datasets, normalized, found the 2000 most variable genes and scaled for each dataset using *Seurat* (v4.3.0.9001) SplitObject, NormalizeData, FindVariableFeatures and ScaleData

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

494 respectively.^{73,74} For batch correction, we used the FindIntegrationAnchors and IntegrateData functions from *Seurat*. The integrated dataset was then used for scaling (ScaleData) and dimensionality reduction (PCA and UMAP) using RunPCA and RunUMAP, respectively. UMAP dimension reduction and clustering were computed using the first 20 principal components (PCs). The number of PCs capturing most of the variation in our data was selected using *Seurat* function ElbowPlot which visualizes the standard deviation of each PC. Clusters were identified via shared-nearest-neighbor-based (SNN) clustering and further 500 analyzed at a resolution of 0.6. $CD8^+$ cell subset was identified using *scGate* (v1.0.1)³⁴ and subsequently extracted with Seurat subset function.

502 scRNAseq CD8⁺ endogenous and T_{TCR-CA} **analysis**

503 The CD8⁺ subset was used to find the 2000 most variable features (FindVariableFeatures), scale the data 504 (ScaleData), and run dimensionality reduction (runPCA and runUMAP). SNN was used for clustering with 505 a resolution of 0.5 for downstream analysis. Differential gene expression across clusters or condition (e.g. 506 AML(+) vs AML(-)) was computed using *Seurat* FindAllMarkers with default parameters. TCR_{C4}-507 transgene⁺ cells were identified using *scGate* (v1.0.1). For visualization purposes, we used Seurat built-in 508 functions alongside *ComplexHeatmap* (v2.15.1)⁷⁵, *scCustomize* (v1.1.0.9001) [\(https://github.com/samuel](https://github.com/samuel-marsh/scCustomize)509 [marsh/scCustomize\)](https://github.com/samuel-marsh/scCustomize) and *SCP* [\(https://github.com/zhanghao-njmu/SCP\)](https://github.com/zhanghao-njmu/SCP). The pan-cancer CD8⁺ single-cell 510 reference atlas was built using the CD8.thisStudy 10X.seu.rds file³⁵ downloaded from Zenodo and 511 processed using the make.reference function from the *ProjecTILs* R package $(v3.2.0)$.⁷⁶ We then used 512 Run.Projectils function, from the same package, to project the cell states from the query dataset onto the 513 reference.

514 Cell trajectory inference was computed using the *Monocle* R package (v1.3.4), with UMAP used as 515 dimensionality reduction. Single-gene expression patterns along the pseudotime were visualized using the 516 plot genes in pseudotime function in *Monocle*. RNA velocity was conducted by exporting the CD8⁺ T-517 cell Seurat object as an h5ad file using the R package *seurat-disk* (v0.0.0.9020) 518 (https://github.com/mojaveazure/seurat-disk), loading this file in Python (v3.8.14) as AnnData object,⁷⁷ and 519 estimating velocities with the *scvelo* Python package $(v0.2.4)^{41}$ using the deterministic model.⁷⁷

 We classified patients as AML(+) or AML(-) based on the presence of detectable blasts in BM or PB. Three patients lacked BM or PB evaluations at one timepoint each. For two of these patients, we used the donor- recipient (male-female) sex mismatch. Patient 8 at day 49 exhibited cells expressing the female-specific gene *XIST* alongside the AML-associated genes *CD34* and *WT1* **(Extended data Fig. 15A)**; similarly, patient 25 expressed *XIST* in a *RPS4Y1* (male-specific gene) negative region at days 7 and 28, thus classified as AML(+) at these timepoints **(Extended data Fig. 15B)**. Patient 4 was categorized as AML(-) at day 100 526 and AML(+) at day 581, as previously reported.⁴³

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 527 To assess the significance of differences in cell proportions per $CD8^+$ cell state between groups (AML(+) 528 vs AML(-)), a permutation test was applied. Specifically, the permutation test and permutation plot 529 functions from the R package *scProportionTest* (version 0.0.0.9000) 530 (https://github.com/rpolicastro/scProportionTest) were used with default parameters.
- 531 For scRNAseq *in-silico* validation, we compiled scRNAseq datasets from independent studies on 532 AML^{20,22,23,44,45}, lung cancer⁴⁸, pancreatic cancer⁴⁶ and melanoma.⁴⁷ CD8⁺ T cells were identified and 533 extracted using the $scdate^{34}$ R package. These cells were then projected onto the pan-cancer CD8⁺ T cell 534 reference atlas³⁵ using *ProjecTILs* R package.
- 535 The TCR repertoire was analyzed using the R package scRepertoire (v1.10.1).⁷⁸ Initially the degree of single
- 536 cells clonal expansion was defined based on the number of cells sharing the same clonotype: 537 Hyperexpanded (100 < X <= 500), Large (20 < X <= 100), Medium (5 < X <= 20), Small (1 < X <= 5),
- 538 Single $(0 < X < 1)$ The function occupiedscRepertoire was used to visualize the degree of clonal expansion
- 539 by cell-state over time.

540 **In-vitro chronic antigen stimulation model**

- 541 The in-vitro dysfunction model was established as previously described.⁴² The WT1⁺ K562 tumor cell line 542 was transduced with lentiviral constructs to express HLA-A*02:01 and GFP, then sorted for purity using 543 the Sony MA900 cell sorter. Cells where then cultured in media consisting of IMDM with GlutaMAX 544 (Gibco, Life Technologies, #31980030) with 10% FBS, and 1% of penicillin/streptomycin.
- 545 $T_{TCR37-45}$ cells were obtained following previously published protocols.⁴³ We selected TCR-T cells targeting 546 WT1 $_{37-45}$ as K562 cell line primarily express the standard proteasome and is not lysed by T_{TCR-C4} targeting 547 WT1 $_{126-134}$ ⁴³ T cells expressing an irrelevant virus-specific TCR were used as negative control. Co-cultures 548 of T cells with K562 cells were established at a 1:1 and 1:4 E:T ratio (2.5 x 10⁵ T cells, 2.5 x 10⁵ or 1 x 10⁶ 549 tumor cells, respectively). After 3-4 days of coculture, 250 µl of the cell suspension was used for T cell 550 counting and flow-cytometry staining. The remaining cell suspension was spun down, and cells were 551 resuspended in fresh media. A Novocyte 3 lasers flow cytometer was used to quantify GFP^+ tumor cells and 552 T cells and to maintain constant E:T ratios by reseeding K562 cells. Notably, during the peak of T-cell 553 expansion (day 9-13), the volumes of the cocultures were reduced to ensure the reseeding of an adequate
- 554 number of tumor cells, thereby maintaining constant E:T ratios. This protocol was followed for 23 days.

555 **Bulk RNA sequencing**

- 556 Bulk RNA sequencing was performed using BGISEQ-500 platform at BGI Genomics. Briefly, total RNA
- 557 was extracted using the Qiagen RNeasy Micro Kit according to the manufacturer's instructions. For the
- 558 construction of low input polyA mRNA-seq libraries, the *SMARTseq* (v4) Package was used. Sequencing
- 559 was performed on a DNBseq T7 machine (MGI) with paired-end 150 bp reads, generating 30M raw reads
- 560 per sample. Raw sequencing data were filtered and trimmed using the software Soapnuke developed by

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- BGI Genomics. The filtered reads were then aligned to the reference transcriptome using *Bowtie2* (v2.2.5).
- Gene read counts were subsequently generated from the alignment results using *RSEM* (v1.2.8).
- 563 To assess differences over time across conditions (T_{TCR37-45} D0, K562 D14, and K562 D23), we used the
- likelihood ratio test (LRT) with a full model of ~Condition and a reduced model including only the intercept
- 565 (reduced $=$ \sim 1). Normalized counts were obtained using the rlog transformation, and differential expression
- analysis was performed using the R package *DESeq2* (v1.42.0). We manually curated a list of genes of
- interest (**Supplementary Table 10**) and filtered the results to retain only those genes that were significant
- (padj < 0.05) with an absolute log2 fold-change > 1). For visualization purposes, average normalized counts
- of biological replicates were calculated using the avereps function from the R package *limma* (v3.56.2) and
- visualized using the R package *pheatmap* (v1.0.12). To visualize the expression patterns of manually
- curated gene signatures, we calculated z-scores for the averaged normalized counts across conditions
- 572 (T_{TCR37-45} D0, K562 D14, and K562 D23). Finally, to compare the enrichment of scRNAseq-derived gene
- signatures (top 50 differentially expressed genes) and of a manually curated exhaustion signature across
- 574 conditions, we used the *hciR* (v1.7) function fgsea all with default parameters and plot fgsea for plotting.
- .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 619 18. Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P.S. Combination Immunotherapy 620 with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. *Cancer Cell* 621 **36**, 471-482 (2019).
- 622 19. Hirayama, A.V., et al. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of 623 CD19 CAR T-cell therapy for large B-cell lymphoma. *Blood Adv* **8**, 453-467 (2024).
- 624 20. Penter, L.*, et al.* Mechanisms of response and resistance to combined decitabine and 625 ipilimumab for advanced myeloid disease. *Blood* (2023).
- 626 21. Rutella, S., et al. Immune dysfunction signatures predict outcomes and define checkpoint 627 blockade-unresponsive microenvironments in acute myeloid leukemia. *The Journal of* 628 *clinical investigation* 132(2022).
- 629 22. Mazziotta, F., et al. CD8+ T-cell Differentiation and Dysfunction Inform Treatment 630 Response in Acute Myeloid Leukemia. *Blood* (2024).
- 631 23. Abbas, H.A.*, et al.* Single cell T cell landscape and T cell receptor repertoire profiling of 632 AML in context of PD-1 blockade therapy. *Nature communications* **12**, 6071-6071 (2021).

633 24. Zeidner, J.F., et al. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in 634 Relapsed/Refractory Acute Myeloid Leukemia. *Blood cancer discovery* **2**, 616-629 (2021).

- 635 25. Penter, L. & Wu, C.J. Therapy response in AML: a tale of two T cells. *Blood* **144**, 1134-1136 636 (2024).
- 637 26. Döhner, H.*, et al.* Diagnosis and management of AML in adults: 2017 ELN 638 recommendations from an international expert panel. *Blood* 129, 424-447 (2017).
- 639 27. Schmid, C.*, et al.* Donor lymphocyte infusion in the treatment of first hematological 640 relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: 641 a retrospective risk factors analysis and comparison with other strategies by the EBMT 642 Acute Leukemia Working Party. *J Clin Oncol* **25**, 4938-4945 (2007).
- 643 28. Berger, C., et al. Adoptive transfer of effector CD8+ T cells derived from central memory 644 cells establishes persistent T cell memory in primates. *J Clin Invest* **118**, 294-305 (2008).
- 645 29. Schmidt, F.*, et al.* In-depth analysis of human virus-specific CD8(+) T cells delineates 646 unique phenotypic signatures for T cell specificity prediction. *Cell Rep* 42, 113250 (2023).
- 647 30. Quintelier, K.*, et al.* Analyzing high-dimensional cytometry data using FlowSOM. *Nat* 648 *Protoc* **16**, 3775-3801 (2021).
- 649 31. Larbi, A. & Fulop, T. From "truly naïve" to "exhausted senescent" T cells: When markers 650 predict functionality. *Cytometry Part A* 85, 25-35 (2014).
- 651 32. Gattinoni, L., Speiser, D.E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and 652 disease. *Nature Medicine* **23**, 18-27 (2017).
- 653 33. Wherry, E.J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. *Nat Rev* 654 *Immunol* **15**, 486-499 (2015).
- 655 34. Andreatta, M., Berenstein, A.J. & Carmona, S.J. scGate: marker-based purification of cell 656 types from heterogeneous single-cell RNA-seq datasets. *Bioinformatics (Oxford, England)* 657 **38**, 2642-2644 (2022).
- 658 35. Zheng, L., et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. *Science (New* 659 *York, N.Y.)* **374**, abe6474-abe6474 (2021).
- 660 36. Szabo, P.A., et al. Single-cell transcriptomics of human T cells reveals tissue and activation 661 signatures in health and disease. *Nature communica?ons* **10**, 4706-4706 (2019).

- 749 76. Andreatta, M., et al. Interpretation of T cell states from single-cell transcriptomics data 750 using reference atlases. *Nature Communications* **12**, 2965-2965 (2021).
- 77. Wolf, F.A., Angerer, P. & Theis, F.J. SCANPY: large-scale single-cell gene expression data analysis. *Genome biology* **19**, 15-15 (2018).
- 78. Borcherding, N., Bormann, N.L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. *F1000Research* **9**, 47-47 (2020).
- 79. Trapnell, C.*, et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol* **32**, 381-386 (2014).
- 757 80. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* **15**, 550-550 (2014).
-

Acknowledgements

 We thank all members of the Chapuis and Greenberg lab for their contribution to the manuscript; the Fred 762 Hutchinson Cancer Center Good Manufacturing Practice Cell Processing Facility for generating $T_{TCR\text{-}C4}$;
763 the Immune Monitoring Laboratory for generating tetramers; the Flow Cytometry Facility for providing the Immune Monitoring Laboratory for generating tetramers; the Flow Cytometry Facility for providing instruments and assistance in flow cytometry assays. We received funding from grant no. P01CA18029-41 (P.D.G.), grant no. NIH-5K08CA169485 (A.G.C.), NIH-T32CA080416 (M.C.L.), the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Center (A.G.C., F.M.), Damon Runyon (A.G.C.), the Guillot Family ZachAttacksLeukemia Foundation, Parker Institute for Cancer Immunotherapy (P.D.G.),

Gabrielle's Angel Foundation, the V Foundation, and Juno Therapeutics. We thank all the patients who

 participated in this study.

Contributions

Conception and design were performed by P.D.G., A.G.C., F.M., M.B., and T.M.S. Collection and assembly

- of data were carried out by F.M., L.M., A.G.C., D.N.E., M.B., V.V., D.H. Data analysis and interpretation
- were performed by F.M., L.M., T.T., V.V., R.G., F.M., A.G.C., and P.D.G. All of the authors contributed to the writing of the manuscript. Final approval of the manuscript was given by all of the authors.
-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

777 **Table 1**

778

Table 1 Clinical characteristics of AML patients receiving T_{TCR-C4} infusions. This table summarizes the clinical data of patients with AML relapsed/refractory after HCT, who received T_{TCR-C4} infusions.

781 *AML: Acute Myeloid Leukemia, HCT: Hematopoietic Cell Transplantation, NED: No Evidence of Disease, MRD: Measurable* 782 *Residual Disease, EBV: Epstein-Barr Virus, CMV: Cytomegalovirus.*

783

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

784
785
786
787
788
789 of T_{TCRC4} in PBMCs collected after the first T_{TCR-C4} infusion for all patients (n =15), with data points representing individual samples at different timepoints post-infusion. Each patient is represented by a distinct color, and red arrows indicate the percentage of WT1-specific CD8⁺ T cells already present at day 0. **(B)** Boxplots comparing the percentage of T_{TCRC4} (log scale, y-axis) after the first infusion (x-axis), colored by the number of infusions (light blue for ≤ 2 infusions; dark orange > 2 infusions). The

It is made available under a CC-BY-NC-ND 4.0 International license.

790 horizontal dashed red line indicates the 3% threshold used to define persisting T_{TCRC4} cells. Statistical significance was determined
791 using Kruskal-Wallis test, with $p < 0.05$ considered significant. (C) Line pl using Kruskal-Wallis test, with $p < 0.05$ considered significant. **(C)** Line plot illustrating the percentage of T_{TCRCA} (y-axis) cells derived from EBV-specific substrate cells (dark orange) or CMV-specific substrate cells (dark violet) over a 28-day period (x-axis) 793 after the first infusion. Statistical significance was determined using Wilcoxon Rank Sum test. (* p < 0.05, ** p < 0.01) **(D)** Boxplots showing differential abundance analysis of CMV-specific (dark violet) and EBV-specific (dark orange) CD8⁺ T-cell subsets derived
795 from the analysis of mass cytometry data.²⁹ CD8⁺ T-cell subsets are defined based o From the analysis of mass cytometry data.²⁹ CD8⁺ T-cell subsets are defined based on marker co-expression showed in Extended data Fig. 7B. A generalized linear model was used to compute differential cluster abundance b data Fig. 7B. A generalized linear model was used to compute differential cluster abundance between the two conditions (CMV \overline{PSV}), with adjusted p-values (threshold for significance of $p<0.05$) displayed above each comparison. ,
797
798

It is made available under a CC-BY-NC-ND 4.0 International license.

799

801 markers across five CD8⁺ PB subsets annotated as Naïve-like (CD45RA, CCR7, CD27, CD28), Tem (CD28, CD27, Ki67, CD38, 802 TIGIT, PD1, Tbet), T_{TCRC4} Tem (TETRAMER, CD28, Ki67, CD38, TIGIT, GZMB, Tbet, KLRG1, GNLY), T 802 TIGIT, PD1, Tbet), T_{TCRC4}_Tem (TETRAMER, CD28, Ki67, CD38, TIGIT, GZMB, Tbet, KLRG1, GNLY), Temra (CD45RA, CD57, KLRG1, GZMB, Tbet), T_{TCRC4}_Temra (TETRAMER, GNLY, KLRG1, TIM3, GZMB, Tbet). The median marker express 803 CD57, KLRG1, GZMB, Tbet), T_{TCRC4}_Temra (TETRAMER, GNLY, KLRG1, TIM3, GZMB, Tbet). The median marker expression identifies the markers that characterize each subset with red indicating high expression and blue low. Th identifies the markers that characterize each subset with red indicating high expression and blue low. The data were scaled after

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

aggregation to highlight population-level differences between tetramer⁺ and tetramer⁻ samples, ensuring a clear visualization of 806 marker expression patterns across subsets. Hierarchical clustering on the left dendro 806 marker expression patterns across subsets. Hierarchical clustering on the left dendrogram groups markers based on their expression patterns, revealing co-occurring markers across subsets, while the top dendrogram shows 807 patterns, revealing co-occurring markers across subsets, while the top dendrogram shows relationships between subsets based on 808 their marker profiles, revealing similarities and differences. The K-means algorithm wa 808 their marker profiles, revealing similarities and differences. The K-means algorithm was applied to further group the clusters by similarity into three groups marked by the numbers (1,2,3) at the top of the heatmap. Da 809 similarity into three groups marked by the numbers (1,2,3) at the top of the heatmap. Data were derived from spectral flow-
810 cytometry analysis. (B) UMAP plots showing the two-dimensional distribution of the annota **810** cytometry analysis. **(B)** UMAP plots showing the two-dimensional distribution of the annotated CD8⁺ T-cell subsets, with the plots 811 colored according to the subset annotation and split by timepoint. The table s 811 colored according to the subset annotation and split by timepoint. The table shows the absolute numbers of T_{TCR-C4} Tem and T_{TCR-C4} Tem and T_{TCR-C4} Tem (blue) and $\frac{812}{\pi}$ Cases 1.1 Tem and T_{TCR}-C4 Tem (blu 812 $_{\text{C4}}$ Temra cells at each timepoint (T1, T2, T3, T4). **(C)** Contour plots illustrating the gating strategy for $T_{\text{TCR-C4}}$ Tem (blue) and 813 $T_{\text{TCR-C4}}$ Temra (red). This strategy starts by identifying the CD3 813 T_{TCR-C4} Temra (red). This strategy starts by identifying the CD3⁺CD8⁺ cell population, followed by selecting tetramer⁺ CD8⁺ cells.
814 Cells are then gated based on Ki67 expression, with Ki67 cells (red) cla Cells are then gated based on Ki67 expression, with Ki67 cells (red) classified as T_{TCR-C4} Temra and Ki67⁺ cells (blue) as T_{TCR-C4} Tem. This gating strategy is based on the marker expression shown in the heatmap in 815 $_{\text{C4}}$ Tem. This gating strategy is based on the marker expression shown in the heatmap in Fig. 2A. (D) Boxplots depicting the percentage (y-axis) of T_{rCRC4} Tem and T_{TCRC4} Temra populations identified in Fig. 2 816 percentage (y-axis) of T_{TCRCA} Tem and T_{TCRCA} Temra populations identified in Fig. 2C over time (x-axis, from T1 to T4). Statistical significance was assessed using Kruskal-Wallis test (threshold for significance: significance was assessed using Kruskal-Wallis test (threshold for significance: p< 0.05). (E) Boxplot showing the percentage (y-
818 axis) of cytotoxic KLRG1⁺, CD57⁺, GNLY⁺ (dark red) compared to exhausted TIM3⁺, axis) of cytotoxic KLRG1+, CD57+, GNLY+ (dark red) compared to exhausted TIM3+, PD1+, TIGIT+ (dark green) T cells among 819 T_{TCRC4}_Temra. Statistical significance was assessed using the Wilcoxon rank-sum test, with a significance threshold of p < 0.05.
820 (F) Boxplots displaying the percentage (y-axis) of cytotoxic (dark red) compared t 820 **(F)** Boxplots displaying the percentage (y-axis) of cytotoxic (dark red) compared to exhausted (dark green) T cells among 821 T_{TCRC4} Temra over time (x-axis, T1 to T4). **(G)** Line plot showing the T_{TCRC4} TFNg⁺ c 821 T_{TCRC4}_Temra over time (x-axis, T1 to T4). **(G)** Line plot showing the T_{TCRC4} ⁺IFNg⁺ cells following WT1-peptide stimulation. The x axis represents the days from the first infusion, while the y axis indicates 822 x axis represents the days from the first infusion, while the y axis indicates the percentage of tetramer⁺IFNg⁺ cells (log10 scale) gated on CD8⁺ T cells. gated on CD8⁺ T cells. 824

28

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Fig. 3 Single cell transcriptomic analysis of endogenous, $T_{TCRC4}CD8^+$ **T-cell states and their differentiation dynamics.** (A) **827** Heatmap showing the top 10 differentially expressed genes identified within each clus 827 Heatmap showing the top 10 differentially expressed genes identified within each cluster. The "top 10" refers to the 10 genes with
828 the most significant differential expression across the identified clusters. The de the most significant differential expression across the identified clusters. The dendrogram on the left displays the similarity between 829 the 13 clusters, which were determined through unsupervised clustering based on gene co-expression patterns. The top dendrogram
830 shows the relationships between the genes based on their expression patterns. To furth 830 shows the relationships between the genes based on their expression patterns. To further refine this clusters, a K-means algorithm
831 was applied to group the 13 clusters into 5 main categories, labeled 1 to 5 on the 831 was applied to group the 13 clusters into 5 main categories, labeled 1 to 5 on the left side of the heatmap. Blue represents low gene expression, while red indicates high gene expression. (B) UMAP plot illustrating the expression, while red indicates high gene expression. **(B)** UMAP plot illustrating the distribution of CD8⁺ T cells (endogenous and $\overline{833}$ T_{TCR-C4}⁺) on a two-dimensional space. T_{TCR-C4}⁺ cells were identified TrcR-C4⁺) on a two-dimensional space. TrcR-C4⁺ cells were identified using scGate,³⁴ an R package which scores cells based on TCR_{C4} expression and defines thresholds to classify cells as positive or negative for t TCR_{C4} expression and defines thresholds to classify cells as positive or negative for the population of interest. TCR_{C4}+ cells are colored in dark red, while TCR_{C4} cells (endogenous) are represented in light grey. **(C)** UMAP plot displaying the two-dimensional distribution of annotated CD8⁺ T-cell transcriptional states, colored by subset. **(D)** distribution of annotated CD8⁺ T-cell transcriptional states, colored by subset. **(D)** Violin plot illustrating the distribution of CD8⁺ T-cell subsets identified through gene expression (Fig. 3A) and TCR_{C4} score (Fi 837 T-cell subsets identified through gene expression (Fig. 3A) and TCR_{C4} score (Fig. 3B) along the principal component 1 (PC₋₁) axis. Each violin represents a different CD8⁺ T-cell state. The proximity of each subs axis. Each violin represents a different CD8⁺ T-cell state. The proximity of each subset along PC_1 (y-axis) indicates transcriptional similarity, with subsets closer together showing more similar gene expression profil 839 similarity, with subsets closer together showing more similar gene expression profiles **(E)** UMAP plot illustrating the inferred 840 developmental trajectory of CD8⁺ T-cell transcriptional states, as predicted by Monocle.⁷⁹ The color scale, ranging from blu to orange/yellow, represents the pseudotime, where blue indicates earlier developmental 841 orange/yellow, represents the pseudotime, where blue indicates earlier developmental stages and orange/yellow indicates later stages of the trajectory. (F) Boxplot showing the distribution of the 5 CD8⁺ T-cell subse stages of the trajectory. **(F)** Boxplot showing the distribution of the 5 CD8⁺ T-cell subsets (y-axis) along the pseudotime (x-axis).
843 The position of the boxes along the pseudotime axis provides context for how th 843 The position of the boxes along the pseudotime axis provides context for how the subsets are positioned within the developmental trajectory, with subsets at lower pseudotime values representing earlier stages of differ 844 trajectory, with subsets at lower pseudotime values representing earlier stages of differentiation, while those at higher pseudotime values correspond to later stages. (G) Line plots displaying the smoothed gene expres 845 values correspond to later stages. **(G)** Line plots displaying the smoothed gene expression of selected genes characterizing the 5
846 CD8⁺ T-cell subsets along the pseudotime. These plots illustrate the dynamic chan 846 CD8⁺ T-cell subsets along the pseudotime. These plots illustrate the dynamic changes in gene expression (y-axis) as cells progress along the inferred trajectory (x-axis). The smoothed curves show how the expressio 847 along the inferred trajectory (x-axis). The smoothed curves show how the expression of each gene varies at different pseudotime points. (H) UMAP plot colored by the annotated CD8⁺ subsets overlaid with the predicted points. **(H)** UMAP plot colored by the annotated CD8⁺ subsets overlaid with the predicted velocity stream computed through scVelo.⁴¹ The velocity streams represent the predicted direction and magnitude of gene expressi scVelo.⁴¹ The velocity streams represent the predicted direction and magnitude of gene expression changes for each individual cell, 850 providing insights into the dynamic transitions between cellular states. These strea 850 providing insights into the dynamic transitions between cellular states. These streams highlight the likely trajectories cells follow as they evolve over time, offering a predictive view of future cellular states based as they evolve over time, offering a predictive view of future cellular states based on current transcriptional dynamics. 852

It is made available under a CC-BY-NC-ND 4.0 International license.

It is made available under a CC-BY-NC-ND 4.0 International license.

Fig. 4 AML induces T_{TCRC4} **NKL/Temra differentiation skewing.** (A) UMAP plot of CD8⁺ T cells colored by density and split by group (AML(-) and AML(+)). AML(+) samples are those in which leukemic cells were detected i 855 by group (AML(-) and AML(+)). AML(+) samples are those in which leukemic cells were detected in BM or PB, while AML(-) samples lack detectable leukemic cells. The plot shows the two-dimensional distribution of CD8+ T cells, with color intensity 857 representing cell density, where blue indicates lower density and yellow indicates higher density. Dashed lines highlight areas of 858 highest cell density in both AML(+) and AML(-) groups. (B) Point-range plot showin 858 highest cell density in both AML(+) and AML(-) groups. **(B)** Point-range plot showing the pairwise (AML(+) vs. AML(-))
859 proportional difference for each CD8⁺ T-cell subset. Colors indicate the statistical signific 859 proportional difference for each CD8⁺ T-cell subset. Colors indicate the statistical significance (red: FDR < 0.05, blue: FDR > \geq 860 0.05); vertical dashed lines mark the absolute value of log2FD cutoff for sig 860 0.05); vertical dashed lines mark the absolute value of log2FD cutoff for significance. **(C)** Heatmap displaying DGE of NKL genes 861 across the CD8⁺ T-cell subsets split horizontally by AML(-) vs. AML(+), with each 861 across the CD8⁺ T-cell subsets split horizontally by AML(-) vs. AML(+), with each condition showing the gene expression patterns 862 for CD8+ T-cell subsets. Blue indicates low expression, while red indicates high ex 862 for CD8+ T-cell subsets. Blue indicates low expression, while red indicates high expression. Dashed boxes highlight NKL/Temra
863 genes, emphasizing their relative expression across the two conditions. (D) Heatmap depi 863 genes, emphasizing their relative expression across the two conditions. **(D)** Heatmap depicting significant DEGs across three conditions: T_{TCR37-45} D0 (T_{TCR37-45}-only), K562 D13 (T_{TCR37-45} T cells after 13 days o 864 conditions: $T_{TCR37-45}$ D0 ($T_{TCR37-45}$ -only), K562 D13 ($T_{TCR37-45}$ T cells after 13 days of coculture with K562 AML cell line), Significance was determined using the Likelihood 865 K563_D23 ($T_{TCR37-45}$ T cells after 23 days of coculture with K562 AML cell line). Signifcance was determined using the Likelihood
866 Ratio Test in DESeq2,⁸⁰ with genes filtered for adjusted p-value (FDR < 0.05). Ratio Test in DESeq2,⁸⁰ with genes filtered for adjusted p-value (FDR < 0.05). Color intensity represents relative gene expression, with blue indicating low expression and red indicating high expression. (E) Boxplots ill with blue indicating low expression and red indicating high expression. (E) Boxplots illustrating the z-score of Exhaustion, NK-868 like, Naïve-like and Tem signatures across the three conditions (co-culture timepoints). **(F)** Heatmap illustrating the enrichment of 869 scRNAseq-derived (TTCRC4, Tem, Naïve.like, NKL.Temra, ISG, Tmem.prolif) and manually curated exhaustion markers across three conditions: K562 D13 vs. T_{TCR37-45} D0, K562 D23 vs. T_{CR37-45} D0, K562 D23 vs. K562 D13. 870 three conditions: K562_D13 vs. T $_{TCR37-45}$ _D0, K562_D23 vs. T $_{TCR37-45}$ _D0, K562_D23 vs. K562_D13. The signatures shown are derived from the top 50 DEGs for each subset from scRNAseq dataset. Additionally, a manuall 871 derived from the top 50 DEGs for each subset from scRNAseq dataset. Additionally, a manually curated exhaustion signature is 872 included. Each row represents the relative enrichment of these gene signatures in the com 872 included. Each row represents the relative enrichment of these gene signatures in the comparison of interest, while the color interestive indicates the degree of enrichment: red indicates high enrichment, while blue in 873 intensity indicates the degree of enrichment: red indicates high enrichment, while blue indicates low enrichment. The comparison group correspond to time point during coculture with the K562 cell line. $T_{TCR37-45}$ re 874 group correspond to timepoint during coculture with the K562 cell line. $T_{TCR37-45}$ represents the baseline ($T_{TCR37-45}$ -only condition)
875 (G) UMAP plot showing the distribution of CD8⁺ T-cell states from a publ **(G)** UMAP plot showing the distribution of CD8⁺ T-cell states from a published independent dataset used as reference atlas.³⁵
876 Dashed line indicates the UMAP coordinates of Tex CD8⁺ T-cell subset. **(H)** UMAP p Dashed line indicates the UMAP coordinates of Tex CD8⁺ T-cell subset. **(H)** UMAP plot of CD8⁺ T-cell reference atlas (light grey) overlaid with projections (dark red) of CD8⁺ T cells collected from various independen 877 overlaid with projections (dark red) of $CD8^+$ T cells collected from various independent published scRNAseq datasets (queries) of $AD878$ AML^{20,22,23,44,45}, pancreatic cancer,⁴⁶, melanoma, ⁴⁷ and lung cancer.⁴⁸ AML^{20,22,23,44,45}, pancreatic cancer,⁴⁶, melanoma, ⁴⁷ and lung cancer.⁴⁸ Dashed line indicates the area corresponding to Tex. 879

It is made available under a CC-BY-NC-ND 4.0 International license.

880

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

882 Fig. 5 Azacitidine as a potential boost for T_{TCR-C4} *in vivo* function and persistence (A) Timeline of patient's treatment regimen.
883 Dark red highlights timeframes with detectable BM AML (B) Percent of BM BRISHER DARK red highlights timeframes with detectable BM AML **(B)** Percent of BM AML blasts (y-axis, log scale) by multiparametric flow cytometry (MFC) at specific timepoints (black dots, dark red shaded area). The horizo flow cytometry (MFC) at specific timepoints (black dots, dark red shaded area). The horizontal dashed line represents the sensitivity 885 limit of MFC. **(C)** Multimer⁺ cells/ μ l and **(D)** Percent multimer⁺ of CD8⁺ T cells in PB (black dots) and BM (red dots) collected before the start of Azacitidine **(E)** UMAP 886 before and after T_{TCR-C4} infusions. The red arrow indicates the lack of T_{TCR-C4} persistence before the start of Azacitidine **(E)** UMAP
887 blots showing a blast score (dark red) calculated based on the co-expressi 887 plots showing a blast score (dark red) calculated based on the co-expression of *CD34* and *XIST* (a female-specific gene) in a patient 888 previously transplanted with a sex-mismatched donor (female patient, male dono 888 previously transplanted with a sex-mismatched donor (female patient, male donor). The score was used to identify cells expressing a high blast score. Additionally, *WTI* expression across all cell populations is shown. 889 a high blast score. Additionally, *WT1* expression across all cell populations is shown. Cells with high expression of each marker 890 are highlighted in red, while other cells appear in grey. (F) Violin plot of the *W* 890 are highlighted in red, while other cells appear in grey. **(F)** Violin plot of the *WT1* expression (y-axis) across the timepoints analyzed after first infusion of T_{TCR-C4} (x-axis, d265, d405, d1322, d1343). Violin p 891 after first infusion of T_{TCR-C4} (x-axis, d265, d405, d1322, d1343). Violin plots are colored by timepoint. **(G)** UMAP plots display the distribution of total PB CD8⁺ T cells from the scRNAseq dataset, with the $T_{$ the distribution of total PB CD8⁺ T cells from the scRNAseq dataset, with the T_{TCR-C4} subset from patient 8 highlighted in dark red.
893 Single-cell points represent individual cells, while kernel density contours (al 893 Single-cell points represent individual cells, while kernel density contours (also in dark red) depict the density of T_{TCR-C4} cells within the CD8⁺ T cell landscape. The plots are stratified by timepoints post-inf 894 within the CD8⁺ T cell landscape. The plots are stratified by timepoints post-infusion: (day 49, day 256, day 405, day 1322, and 895 day 1343). This series illustrates the spatiotemporal dynamics of the $T_{TCR,C4}$ su 895 day 1343). This series illustrates the spatiotemporal dynamics of the T_{TCR-C4} subset, showing its distribution in relation to the 896 broader PB CD8⁺ T cell population and highlighting potential transcriptional ch 896 broader PB CD8⁺ T cell population and highlighting potential transcriptional changes over time. Red arrows were added manually 897 to indicate the different skewing of T_{TCR-C4} across the timepoints examined. (H) U to indicate the different skewing of T_{TCR-C4} across the timepoints examined. **(H)** UMAP plots showing the distribution of PB CD8⁺ 898 T cells, with the density contours highlighting cells with high self-renewing (dark 898 T cells, with the density contours highlighting cells with high self-renewing (dark green) and NK-like (dark red) scores. The self-
899 renewing score was calculated based on a set of stem-like/survival genes (TCF7, LE 899 renewing score was calculated based on a set of stem-like/survival genes (*TCF7*, *LEF1*, *SELL*, *CCR7*, *BCL2*, *IL7R*, *CD27*, *CD28*) and the NK-like score was based on NK-associated genes (*ZEB2*, *SIPR5*, *CX3CR1* 900 and the NK-like score was based on NK-associated genes (*ZEB2*, *S1PR5*, *CX3CR1*, *KLRG1*, *NKG7*, *FCRL6*, *KLRD1*, *ADGRG1*). 901 The plots are color-coded by score (light grey for the background, darker shades indicating higher scores). Cells with scores above
902 the 75th percentile for each gene set are highlighted with density in dark green f 902 the 75th percentile for each gene set are highlighted with density in dark green for high self-renewing score cells and dark red for 903 high NK-like score cells. (I) The plot shows the temporal changes in the self-903 high NK-like score cells. **(I)** The plot shows the temporal changes in the self-renew (left) and NK-like (right) scores of T_{TCR-C4} from patient 8. The smoothed trends of the scores were calculated using LOESS regres 904 from patient 8. The smoothed trends of the scores were calculated using LOESS regression at multiple timepoints. The dark green (self-renew) and dark red (NK-like) lines represent the smoothed score trends, with shaded 905 (self-renew) and dark red (NK-like) lines represent the smoothed score trends, with shaded areas indicating the confidence interval.
906 The y-axis reflects the score expression values. (J) Dot plot displaying the expr 906 The y-axis reflects the score expression values. **(J)** Dot plot displaying the expression of the self-renew and NK-like scores across 907 timepoints post-infusion. The size of each dot corresponds to the expression level of the respective score and the color indicates the relative intensity of the expression. (K) Stacked plot showing cell count of T_{TCR 908 the relative intensity of the expression. **(K)** Stacked plot showing cell count of T_{TCRC4} in specific clonal frequency ranges over time (d256, d405, d1322, d1343). Colors indicate the clonal frequencies. **(L)** Stack 909 (d256, d405, d1322, d1343). Colors indicate the clonal frequencies. (L) Stacked plot showing cell count for BM T_{TCRC4} within specific clonal frequency ranges at d1322 and d1343. Colors indicate the clonal frequencies 910 specific clonal frequency ranges at d1322 and d1343. Colors indicate the clonal frequencies. **(M)** Cartoon (created with Biorender) showing the influence of blasts and azacitidine on T_{TCR-C4} . The red area under the showing the influence of blasts and azacitidine on T_{TCR-C4} . The red area under the curve represents the blasts percentage (y-axis) 912 over time (x-axis). Blasts induce T_{TCR-C4} skewing towards NKL and cell death. However, prolonged exposure to azacitidine allows 913 T_{TCR-C4} to maintain self-renewal, facilitating persistence and long-term diseas $T_{TCR\text{-}C4}$ to maintain self-renewal, facilitating persistence and long-term disease control.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 1

Extended data Fig. 1: Flow diagram of patients enrolled on the clinical study. Follow-up of the 67 patients screened for participation in the study and the 44 patients who signed the informed consent. Patients with no detectable disease post-HCT were assigned to the Prophylactic Arm¹, while those with evidence of disease post-HCT were treated in the Treatment Arm described here. A total of 44 pt/donor pairs were enrolled pre-HCT, TCR_{C4} transduced cells were initiated for 38 patients, among whom 12 disease-free (Arm 1) and 15 relapsed/refractory (Arm 2) patients received TCR_{C4} transduced cells. An additional patient was considered not evaluable for response outcomes as this patient received <10 % of the targeted dose and was unable to receive further infusions due to inability to generate additional T cells from the donor.

It is made available under a CC-BY-NC-ND 4.0 International license.

Extended data Fig. 2

Extended data Fig. 2: Flow diagram of patients'treatment history. The cohort included 15 patients who relapsed after HCT. 7 patients received salvage chemotherapy before the infusion of TrcR-C4, while 6 patients had two HCTs before the infusion, and 1 patient among them also received salvage chemotherapy. At the time of TCR-C4 infusion, 7 patients had detectable AML, while 8 patients were in remission (AML-negative). The time from relapse post-HCT to TCR-C4 infusion ranged from 34 to 700 days, with a median of 179 days.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 3

Extended data Fig. 3. Study schema. The first 8 patients who received T_{TCR-C4} after post-HCT relapse (Treatment Arm, Stage1) received 4 escalating infusions of $10^9 \text{-} 10^{10}$ /m² 14 days apart, the last infusion followed by s.c. low-dose IL2 for 14 days. After safety of the highest dose was established, all subsequent patients received 2 infusions of $10^{10}/m^2$ T_{TCR-C4} 28 days apart, the second infusion followed by s.c. low-dose IL2 for 14 days**.**

Extended data Fig. 4

Extended data Fig. 4. Swimmer Plot of Patient Responses.

The swimmer plot illustrates the response duration for patients enrolled in the trial. Time 0 represents the relapse or persistent disease after the first HCT that qualified patients for trial inclusion. The end of each bar indicates the date of death or last follow-up, with arrows marking ongoing responses. "Salvage" denotes any salvage strategy, including chemotherapy, radiotherapy, or intrathecal treatment. Salvage with a second HCT is marked by a triangle.

Patient 8: A patient who had MRD post HCT and received T_{TCR-C4} with MRD. She later underwent azacitidine salvage treatment for persistent MRD (duration shown as a gray line). The patient then relapsed, underwent additional salvage chemotherapy, azacitidine, and received a second T_{TCR-C4} infusion. Following this, she experienced prolonged MRD+ stable disease with detectable long-term persisting PB T_{TCR-C4}. Eventually, the disease progressed, and she relapsed and died (see **Results** for more details).

Patient 6: A patient who received salvage chemotherapy followed by a second HCT which resulted in no evaluable disease. Subsequently, she received four T_{TCR-C4} infusions. The patient was alive at the last follow-up.

Patient 2: A patient who, after salvage treatment, underwent a second HCT while in overt disease. She remained MRD-positive 28 days postsecond-HCT. She received four T_{TCR-C4} infusions. Eventually, she achieved a MRD negative status. The patient was alive at the last follow-up.

Patient 4: A patient who achieved a complete remission after a second HCT. However, after ~15 months, he experienced extramedullary relapse, treated with azacitidine and radiotherapy which achieved no evaluable disease. He maintained remission for \sim 1 year after the first TrcR-C4 infusion. Subsequently, he relapsed extramedullary and was refractory to an additional TrcR-C4 infusion. Further details on this case and mechanisms of AML escape have been described previously.²

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 5

Extended data Fig. 5. Overall survival of AML patients treated with TTCRC4 T cells. Kaplan Meier estimate of overall survival (OS) of 15 AML patients with evidence of disease post-HCT, who were subsequently treated with TTCRC4 T cells

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 6. EBV specific vs. CMV specific TTCR-C4 persistence. (A) Line plots showing the absolute counts (cells/uL) in log scale of PB multimer+ CD8+ T cells collected after T_{TCR-C4} infusion and stratified by virus specificity. EBV-specific cells are represented in dark orange, and CMV-specific cells are represented in dark violet. Data points correspond to individual samples collected at different timepoints post-infusion. **(B)**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Boxplots comparing the percentage of EBV-specific $T_{TCR\text{-}c4}$ cells in Arm 1 (red) and Arm 2 (blue) with the percentage of CMV-specific $T_{TCR\text{-}c4}$ cells in Arm 2 (green) across post-infusion timepoints. The y-axis indicates the percentage (log scale) of TTCR-C4 cells, while the x-axis represents the time post-infusion. Data were derived from flow-cytometry analysis. The horizontal dashed red line indicates the 3% threshold used to define persisting T_{TCR-C4} cells. The y-axis is displayed on a log10 scale. Statistical comparison between all three groups at each time point was performed using a Kruskal-Wallis test, with p-values displayed above the corresponding boxplots. Statistical significance was defined as p < 0.05.

Extended data Fig. 7

A

Extended data Fig. 7. EBV and CMV specific CD8⁺ T-cell states. (A) Multidimensional (MDS) scaling plot illustrates the distribution of samples based on the expression of top varying markers, which are those markers showing the most variation in expression levels across the dataset. These markers are selected for their ability to highlight meaningful differences between samples or conditions. In this context, samples associated with CMV (violet dots) and EBV (orange dots) are plotted along the first two MDS dimensions (MDS dim. 1, MDS dim. 2). This unsupervised method visualizes sample clustering based on marker expression, with dissimilarities calculated using the median expression of markers across all cells in each sample. The plot provides an overview of variance and potential clustering patterns among the samples. **(B)** Heatmap illustrating the median expression levels of 27 markers across four PB CD8+ T cell subsets: Naïve-like (CD95-, CD45RA+, CCR7+, CD27+, CD28+), Effector Memory (Tem) (CD95+, CD45RA-, CD45RO+, CD27+, CD28+, CD127+), Central Memory (Tcm) (CD95+, CD45RA-, CD45RO+, CCR7+, CD27+, CD28+, CD127+), and Effector Memory RA+ (Temra) (CD95+, CD45RA+, CD45RO-, CD57+, KLRG1+). The data are scaled to normalize marker expression across the dataset before clustering, ensuring each marker contributes proportionally to cluster definitions while minimizing the impact of extreme values or outliers. Blue represents lower expression, and red indicates higher expression. Hierarchical clustering on the top dendrogram groups markers based on their expression patterns, revealing co-occurring markers across subsets, while the clustering on the left shows relationships between subsets based on their marker profiles, highlighting their similarities.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 8

Extended data Fig. 8 Persitence and functionality of T_{TCR-CI} **post-first infusion** (A) **Line plot showing the percentage (log scale) of** T_{TCR-CI} **in** PBMCs collected after the first infusion across all patients (n=15), colored by virus-specificity (violet = CMV; orange = EBV), derived from flowcytometry data (B) Line plot showing the T_{TCRCA} ⁺TNF α ⁺ cells following WT1-peptide stimulation. The x axis represents the days from the first infusion, while the y axis indicates the percentage (log10 scale) of Tetramer+ $TNF\alpha^+$ gated on CD8+ T cells, based on flow cytometry data

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 9. Identification of transcriptional endogenous and T_{TCR-C4} CD8⁺ T-cell states. (A) UMAP plot showing the distribution of

It is made available under a CC-BY-NC-ND 4.0 International license.

CD8⁺ T-cell states from a published independent dataset³ used as a reference atlas. **(B)** The UMAP projections of each T-cell state defined in Fig. 3C are overlaid onto the reference atlas as contour plots. Contours corresponding to each subset from the query are color-coded as in Fig. 3C, allowing for easy visualization of the distribution of each subset within the reference atlas. **(C)** Heatmap showing the differential expression of manually curated genes (Supplemental Table 7) across the five annotated CD8⁺ T-cell subsets. Blue and red indicate the relative expression levels of each marker within each subset, with blue representing lower expression and red indicating higher expression. **(D)** Violin plots displaying the expression levels (y-axis) of stem-like (*IL7R*, *TCF7*), activation (*GZMK*, *CD69*), and cytotoxicity/NK-like (*GZMB*, *KLRG1*, *NKG7*, *ZEB2*, *S1PR5*) markers across CD8⁺ T-cell transcriptional states (x-axis). Statistical significance was assessed using the Wilcoxon rank sum test. Asterisks indicate the following thresholds of significance: *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001.

It is made available under a CC-BY-NC-ND 4.0 International license.

Extended data Fig. 10

Extended data Fig. 10. CD8⁺ transcriptional states after TCRC4 removal. (A) UMAP plot depicting the inferred developmental trajectory of $CD8^+$ T-cell transcriptional states, as predicted by Monocle, following the removal of the TCR_{C4} transcript. The color scale, ranging from blu to orange/yellow, represents the pseudotime, where blue indicates earlier developmental stages and orange/yellow indicates later stages of the trajectory.

(B) UMAP plot showing the distribution of CD8+ T-cell transcriptional states after TCRC4 removal, with the same coordinates as panel A. The Tcell subsets are labeled according to the clustering defined in Fig. 3D, providing context for how the subsets are positioned within the developmental trajectory in A.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 11

It is made available under a CC-BY-NC-ND 4.0 International license.

Extended data Fig. 11. In-vitro dysfunction coculture system. (A) Experimental design of the in-vitro model used to study chronic tumor exposure of WT1-specific T cells (T $T_{TCR37-45}$ cells). The diagram shows two conditions with Effector (T $T_{TCR37-45}$) to Target (K562) (E:T) ratios of 1:1 and 1:4. Red arrows indicate tumor re-challenge every 3-4 days, while red circles on the timeline mark the time points when RNA extraction for bulk-RNA sequencing was performed. An irrelevant TCR-expressing T cell line was used as a negative control. The experiment involved exposing transgenic CD8⁺ WT1-specific T cells to HLA-A*0201-transduced K562 cells expressing high levels of WT1. This figure was realized using BioRender. **(B)** Line plots showing the changes in absolute cell counts (y-axis) over time (x-axis, days of coculture) for $T_{TCR37-45}$ (solid lines) and K562 tumor cells (dashed lines) in coculture at E:T ratios of 1:1 and 1:4. The lines for each condition are colored sky blue (1:4 ratio) and tan (1:1 ratio). Cell counting was performed by flow cytometry. **(C)** Line plots showing the T cell to tumor cell ratio (y-axis) changes at the timepoints of tumor re-challenge (x-axis). Each plot represents one condition (left, E:T 1:4; right, E:T 1:1). Cell ratios were calculated based on flow cytometry data.**(D)** Line plots showing the changes in absolute cell counts (y-axis) over time (x-axis, days of coculture) for T cells with irrelevant TCR (solid lines) and K562 tumor cells (dashed lines) in coculture at E:T ratios of 1:1 and 1:4. The lines for each condition are colored sky blue (1:4 ratio) and tan (1:1 ratio). Cell counting was performed by flow cytometry.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 12

Extended data Fig. 12 UMAP projection of KLR dysfunction signatures in CD8⁺ T cells. UMAP plots illustrate the spatial distribution of CD8⁺ T cells based on their expression of published KLR dysfunction gene signatures.⁴⁻⁶ These signatures, derived from prior studies, were applied to our scRNAseq dataset to calculate a score for each cell, reflecting the degree of expression of the KLR dysfunction features. The scores are visualized using a gradient, where blue indicates low expression and red indicates high expression. Regions with high expression (red) align with the subset we identified as Temra NK-like cells, suggesting a functional and phenotypic overlap within this subset.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 13

NK-like score

Extended data Fig. 13 UMAP projection of NK-like module score based on gene expression in a tumor-infiltrating lymphocytes reference atlas.³ UMAP plot projection showing the module score based on the expression of the following genes: *KLRG1*, *KLRD1*, *ZEB2*, *FCRL6*, *ADGRG1*, *S1PR5*, *FCGR3A*, *GZMB*, and *NKG7*. Each point represents an individual cell, and the color scale ranges from light grey (low module score) to dark red (high module score), reflecting the intensity of the gene set expression across cells. The black circle marks the area with the highest NKlike score, indicating the regions where the combined expression of NK-associated genes is most prominent.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Extended data Fig. 14

Extended data Fig. 14. Immunohistochemistry of bone marrow biopsy stained for WT1. This immunohistochemistry image shows a bone marrow biopsy stained for WT1. Black arrows indicate WT1-positive nuclei, visible as distinct dark-stained areas within the cells, which signify expression of the WT1 protein.

It is made available under a CC-BY-NC-ND 4.0 International license.

Extended data Fig. 15

Extended data Fig. 15 Patient 8 blasts and T cells characterization (A) UMAP plot showing a blast score (dark red) calculated based on the coexpression of *CD34* and *XIST* (a female-specific gene) in a patient previously transplanted with a sex-mismatched donor (female patient, male donor). The score was used to identify cells expressing a high blast score. Each UMAP plot represents a different timepoint (day 49, 256, 405, 1322, 1343) after the first infusion, with lightgrey indicating low expression and dark red indicating high expression of the blast score. **(B)** UMAP plot showing a blast score calculated based on the co-expression of *XIST*, *CD34*, *CD33*, and *KIT*. This score was used to visualize cells with high blast scores in bone marrow samples. Each UMAP plot represents a specific timepoint (day 1322 and 1344) post-first TrcR-C4 infusion, (C) Line plot showing platelets and neutrophil absolute counts over time after the first infusion. Platelets (left y-axis, dark blue line plot, measured as platelets/μL \times 1000) and neutrophils (right y-axis, red line plot, measured as ANC/ μ L \times 1000) are shown in relation to the days after the first infusion (x-axis). Vertical dark green dashed lines indicate the timing of azacytidine cycles, while solid orange lines represent the timepoints when BM scRNA-seq was performed.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 $\begin{array}{cc} 0 & 5 \\ \text{UMAP_1} \end{array}$

RPS4Y1

 $\overline{15}$

 10

It is made available under a CC-BY-NC-ND 4.0 International license.

Extended data Fig. 16 UMAP visualization of gene expression in AML patient samples. (A) UMAP plots at day 49 post-first T_{TCR-G4} **infusion** depict the expression patterns of leukemia-associated markers *WT1* and *XIST* (a female-specific gene) in patient 8, previously transplanted with a sex-mismatched donor (female patient, male donor). Additionally, *CD34* expression across all cell populations is shown. Cells with high expression of each marker are highlighted in red, while other cells appear in grey. **(B)** UMAP plots illustrate a longitudinal analysis of leukemia-associated gene expression in patient 26, who was transplanted with a sex-mismatched donor (female patient, male donor), at days 7 (d7) and 28 (d28) post-first TrcR-C4 infusion. *XIST* indicates leukemic cells, while *RPS4Y1* (a malespecific gene) marks non-leukemic cells. Cells with high gene expression are represented in dark red, and those with lower expression appear in light grey.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

References

- 1. Chapuis, A.G.*, et al.* T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. *Nature Medicine* **25**, 1064-1072 (2019).
- 2. Lahman, M.C.*, et al.* Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency. *Science translational medicine* **14**, eabg8070 eabg8070 (2022).
- 3. Zheng, L.*, et al.* Pan-cancer single-cell landscape of tumor-infiltrating T cells. *Science (New York, N.Y.)* **374**, abe6474-abe6474 (2021).
- 4. Mazziotta, F.*, et al.* CD8+ T-cell DiTerentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia. *Blood* (2024).
- 5. Daniel, B., et al. Divergent clonal differentiation trajectories of T cell exhaustion. *Nature immunology* **23**, 1614-1627 (2022).
- 6. Giles, J.R., et al. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. *Nature immunology* **23**, 1600-1613 (2022).